PFAE possibly related to both ICI and TKI
May 13, 2025Endocrine
May 17, 2025AE considered related to TKI
Note: this is a simplified overview. For detailed information, please refer to the product SMPCs.
G≤1 or tolerable G2, thyroid or adrenal dysfunction:
- continue TKI
- supportive care
- endocrine replacement therapy
Intolerable G2, G≥3, ONJ or AST/ALT >3-10xULN and/or bilirubin <2xULN:
- hold TKI
- when resolved to G≤1 or baseline: restart TKI at reduced dose
- if recurrent/intolerant at lowest dose: discontinue TKI
Consider discontinuation TKI in case of:
- ONJ
- severe hemorrhage
- GI perforation/fistula
- acute cardiovascular events
- severe uncontrollable hypertension
- ALT/AST >10x ULN or >3x ULN with bili ≥2x ULN
- nephrotic syndrome
- RPLS